183427-87-4

Basic information

• Product Name: 2-(2-METHOXYPHENOXY)ACETAMIDE
• Synonyms: 2-(2-METHOXYPHENOXY)ACETAMIDE;2-METHOXYPHENOXYACETAMIDE
• CAS NO: 183427-87-4
• Molecular Formula: C₉H₁₁NO₃
• Molecular Weight: 181.19
• Mol File: 183427-87-4.mol
• Article Data: 5

Chemical Properties

• Melting Point: 142°C
• Boiling Point: 357.7°Cat760mmHg
• Flash Point: 198.2°C
• Appearance: /
• Density: 1.17g/cm³
• Vapor Pressure: 2.69E-05mmHg at 25°C
• Refractive Index: 1.53
• CAS DataBase Reference: 2-(2-METHOXYPHENOXY)ACETAMIDE(CAS DataBase Reference)
• NIST Chemistry Reference: 2-(2-METHOXYPHENOXY)ACETAMIDE(183427-87-4)
• EPA Substance Registry System: 2-(2-METHOXYPHENOXY)ACETAMIDE(183427-87-4)

Safety Data

• Hazard Codes: Xi
• Statements: 36/37/38
• Safety Statements: 26-36/37/39
• Hazardous Substances Data: 183427-87-4(Hazardous Substances Data)

Usage

General Description

2-(2-Methoxyphenoxy)acetamide is a chemical compound with the molecular formula C10H11NO3. It is a white solid with a molecular weight of 193.20 g/mol. 2-(2-METHOXYPHENOXY)ACETAMIDE is often used in the field of organic synthesis and medicinal chemistry. It has been studied for its potential pharmacological properties, including anti-inflammatory and analgesic effects. Additionally, 2-(2-Methoxyphenoxy)acetamide has been investigated for its use in the development of new pharmaceutical drugs for various medical conditions. Overall, this compound has shown promise as a valuable chemical in the development of new therapeutic agents.

InChI:InChI=1/C9H11NO3/c1-12-7-4-2-3-5-8(7)13-6-9(10)11/h2-5H,6H2,1H3,(H2,10,11)

Upstream product

• 90-05-1 2-methoxy-phenol 
• 79-07-2 Chloroacetamide 
• 13052-77-2 sodium 2-methoxyphenolate 
• 5633-98-7 potassium guaiacolate 
• 13078-21-2 ethyl 2-(2-methoxyphenoxy)acetate 

Downstream Products

• 1836-62-0 2-(2-methoxy-phenoxy)-ethylamine 
• 18655-51-1 2-(3-Aminopropyl)-1-methoxybenzene 

Relevant articles and documents

A phenoxy acetyl amine compound preparation method and phenoxy acetamide compounds

The invention belongs to the organic intermediates and the technical field of pharmaceutical intermediates, in particular to a phenoxy acetyl amine compound preparation method and phenoxy acetyl amine compound. The present invention provides a preparation method of the pervasive should be good, and green environmental protection, has better popularization and application value. The results show that the embodiment, the invention provides the above-mentioned method can prepare a plurality of phenoxy acetyl amine compound, and the yield can be 76%.

New serotonin 5-HT1A receptor agonists endowed with antinociceptive activity in vivo

We report the synthesis of new compounds 4-35 based on two different openings (A and B) of the chromane ring present in the previously identified 5-HT1A receptor (5-HT1AR) ligand 3. The synthesized compounds were assessed for binding affinity, selectivity, and functional activity at the 5-HT1AR. Selected candidates resulting from B opening were also evaluated for their potential antinociceptive effect in vivo and pharmacokinetic properties in vitro. Analogue 19 [2-(4-{[2-(2-ethoxyphenoxy) ethyl]amino}butyl)tetrahydro-1H-pyrrolo[1,2-c]imidazole-1,3(2H)-dione] has been characterized as a high-affinity and potent 5-HT1AR agonist (K i = 2.3 nM; EC50 = 19 nM). Pharmacokinetic studies indicated that compound 19 displays a good metabolic stability in human liver microsomes (t1/2 ～ 3 h and CLint = 3.5 mL/min/kg, at 5 μM), and a low level of protein binding (25%, at 5 μM). Interestingly, 19 (3 mg/kg, ip, and 30 mg/kg, po) caused significant attenuation of formalin-induced behavior in early and late phases of the mouse intradermal formalin test of pain, and this in vivo effect was reversed by the selective 5-HT1AR antagonist WAY-100635. Thus, the new 5-HT1AR agonist identified in this work, 19, exhibits oral analgesic activity, and the results herein represent a step toward identifying new therapeutics for the control of pain.

1,3-Dioxolane-based ligands as a novel class of α1-adrenoceptor antagonists

1,3-Dioxolane-based compounds (2-14) were synthesized, and the pharmacological profiles at α1-adrenoceptor subtypes were assessed by functional experiments in isolated rat vas deferens (α1A), spleen (α1B), and aorta (α1D). Compound 9, with a pA2 of 7.53, 7.36, and 8.65 at α1A, α1B, and α1D, respectively, is the most potent antagonist of the series, while compound 10 with a pA2 of 8.37 at α1D subtype and selectivity ratios of 162 (α1D/α1A) and 324 (α1D/α1B) is the most selective. Binding assays in CHO cell membranes expressing human cloned α1-adrenoceptor subtypes confirm the pharmacological profiles derived from functional experiments, although the selectivity values are somewhat lower. Therefore, it is concluded that 1,3-dioxolane-based ligands are a new class of α1-adrenoceptor antagonists.